1

ABPI Vision and Narrative

www.abpi.org.uk

Clinicians / Commissioners focused on outcomes and

incentivised and remunerated on the results they achieve

NICE issues Guidelines / Quality Standards to support clinicians through clear advice on best practice, including use

of new technologies

Industry works in partnership with the NHS

to help get maximum value from the new technology (eg through joint working

projects focussed on outcomes etc)

Industry agrees a reimbursement level

which reflects the value that a new technology offers patients and the

NHS

NHS has confidence that it can embrace new technologies in the knowledge they offer value for all appropriate patients –

removes need to undertake value assessments/ negotiations at different

levels

TRUST

TRUST

PATIENTS

ABPI Strategy

www.abpi.org.uk

ABPI Vision and Narrative

Vision

ContextABPI Business

Objectives

TRUST

TRUST

PATIENTS

ABPI Strategy

Clinicians / Commissioners

focussed on outcomes

NICE issues Guidelines /

Quality Standards

Industry agrees a reimbursement

level

NHS has confidence that it can embrace new

technologies

Industry works in partnership with

the NHS

www.abpi.org.uk

The ABPI Vision

• To partner in creating an integrated healthcare system where the NHS efficiently delivers better outcomes for patients through appropriate use of innovative medicines for which industry is fairly rewarded

www.abpi.org.uk

Context

• The NHS is changing, with major implications for patients, clinicians, • managers and for the industry• There is substantial increase in technological advances• There is an increasingly elderly population• UK is lagging behind Europe in health outcomes – particularly most common

cancers, heart attacks and other chronic conditions• There is a need to drive better value, coupled with better outcomes for patients, out

of the healthcare system• The PPRS has, over the last 50+ years, evolved (and continues to evolve), serving

both Government and industry well• The shape of the industry pipeline is an opportunity, re: innovation• Access to new medicines remains an issue, as does use of these medicines by

patients• Expectations of corporate behaviour are concertedly changing, with both

customers and society expecting greater transparency and accountability from business and from individuals (ref MPs)

www.abpi.org.uk

ABPI Business Objectives

Business Priority Objective Metrics

Value and Access:CDF/VBPNew NHSImplementing Quality Outcomes

To formulate an aligned industry position for a sustainable and holistic healthcare system that drives appropriate uptake of innovative medicines. Gain agreement on approach as part of the future PPRS

• Agreed value based reimbursement model• Uptake metric reports• Engagement in National Commissioning

Board and Quality Standards • Acceleration of QIPP focused joint working

activities

Innovation Creating a leading environment for R&D in the UKMaximising the value of our R&D investment

• Industry participation to ensure pilot capability clusters in Immunology & Inflammation is a success & involvement in formulation of future clusters

• Improved transparency, speed, quality & delivery in clinical trials based on OLS recommendations

• Publication of Real World Data Blueprint and Industry Guidance plus broad dissemination of UK leadership position in this area

• Development of and agreement to tangible steps to boost UK investment as part of 2011 Growth Review

Trust & Reputation Build industry’s role as a trusted partner in the healthcare system to create the environment in which long-term commercial and innovation objectives can be achievedInform strategic thinking on communications and stakeholder engagement

• 2011 UK Industry Reputation model results• Increase in positive media reporting and/or

reduction in negative reporting• Partnerships created with external stakeholder

organisations• Reversal in NHS restrictions on industry

access

www.abpi.org.uk

Vision

• To partner in creating a sustainable healthcare environment where the NHS efficiently delivers better outcomes for patients through appropriate use of innovative medicines for which industry is fairly rewarded